Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

被引：20
|
作者：
Lu, L. [1 ,2 ]
Saunders, V. A. [1 ]
Leclercq, T. M. [1 ,2 ]
Hughes, T. P. [1 ,2 ,3 ]
White, D. L. [1 ,2 ,4 ]
机构：
[1] South Australian Hlth & Med Res Inst SAHMRI, Canc Theme, Adelaide, SA, Australia
[2] Univ Adelaide, Sch Med, Discipline Med, Adelaide, SA, Australia
[3] SA Pathol, Dept Haematol, Adelaide, SA, Australia
[4] Univ Adelaide, Sch Med, Discipline Paediat, Adelaide, SA, Australia
来源：
LEUKEMIA | 2015年 / 29卷 / 08期
关键词：
IN-VITRO SENSITIVITY; IMATINIB MESYLATE; LEUKEMIA-CELLS; P-GLYCOPROTEIN; RESISTANCE; INHIBITOR; EFFLUX; ABL;
D O I：
10.1038/leu.2015.35
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1792 / 1794
页数：3
相关论文
共 50 条
  • [1] Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells
    L Lu
    V A Saunders
    T M Leclercq
    T P Hughes
    D L White
    Leukemia, 2015, 29 : 1792 - 1794
  • [2] Karanjin interferes with ABCB1, ABCC1, and ABCG2
    Michaelis, Martin
    Rothweiler, Florian
    Nerreter, Thomas
    Sharifi, Mohsen
    Ghafourian, Taravat
    Cinatl, Jindrich, Jr.
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2014, 17 (01): : 92 - 105
  • [3] What next? Preferably development of drugs that are no longer transported by the ABCB1 and ABCG2 efflux transporters
    van Hoppe, Stephanie
    Schinkel, Alfred H.
    PHARMACOLOGICAL RESEARCH, 2017, 123 : 144 - 144
  • [4] Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib
    Akimitsu Maeda
    Hitoshi Ando
    Kei Irie
    Naoya Hashimoto
    Jun-ichi Morishige
    Shoji Fukushima
    Akira Okada
    Hiromichi Ebi
    Masahide Matsuzaki
    Hiroji Iwata
    Masataka Sawaki
    European Journal of Clinical Pharmacology, 2022, 78 : 1239 - 1247
  • [5] Lipid Regulation of the ABCB1 and ABCG2 Multidrug Transporters
    Hegedus, Csilla
    Telbisz, Agnes
    Hegedus, Tamas
    Sarkadi, Balazs
    Ozvegy-Laczka, Csilla
    ABC TRANSPORTERS AND CANCER, 2015, 125 : 97 - 137
  • [6] Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib
    Maeda, Akimitsu
    Ando, Hitoshi
    Irie, Kei
    Hashimoto, Naoya
    Morishige, Jun-ichi
    Fukushima, Shoji
    Okada, Akira
    Ebi, Hiromichi
    Matsuzaki, Masahide
    Iwata, Hiroji
    Sawaki, Masataka
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (08) : 1239 - 1247
  • [7] IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL
    Rinaldetti, S.
    Pfirrmann, M.
    Manz, K.
    Guilhot, J.
    Panagiotidis, P.
    Spiess, B.
    Seifarth, W.
    Fabarius, A.
    Pagoni, M.
    Dimou, M.
    Dengler, J.
    Waller, C.
    Bruemmendorf, T. H.
    Herbst, R.
    Burchert, A.
    Janssen, C.
    Goebeler, M. E.
    Jost, P. J.
    Hanzel, S.
    Schafhausen, P.
    Prange-Krex, G.
    Illmer, T.
    Janzen, V.
    Klausmann, M.
    Eckert, R.
    Bueschel, G.
    Kiani, A.
    Hofmann, W. -K.
    Mahon, F. -X.
    Saussele, S.
    HAEMATOLOGICA, 2017, 102 : 74 - 74
  • [8] Expression and function of ABCB1 and ABCG2 in human placental tissue
    Kolwankar, D
    Glover, DD
    Ware, JA
    Tracy, TS
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (04) : 524 - 529
  • [9] ABCB1 and ABCG2 expression in the placenta and fetus: an interspecies comparison
    Myllynen, Paivi
    Kummu, Maria
    Sieppi, Elina
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (11) : 1385 - 1398
  • [10] Impact of ABCB1 and ABCG2 Transporter in Outcome of Gallbladder Cancer
    Nimisha
    Saluja, Sundeep S.
    Sharma, Abhay K.
    Nekarakanti, Phani K.
    Apurva, Arun
    Kumar, Arun
    Ahmad, Ejaj
    Husain, Syed A.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2024, 14 (05)
12345